SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO(2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS

The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.

WO 02/76925 (Eli Lilly) describes a series of compounds which are claimed to be histamine H3 antagonists. WO 02/055496 (GlaxoSmithKline) describes a series of piperidine and piperazine derivatives which are claimed to be inducers of LDL-receptor expression. WO 02/12214 (Ortho McNeil Pharmaceutical Inc) describes a series of substituted aryloxyalkylamines which are claimed to be histamine H3 antagonists.

The histamine H3 receptor is expressed in both the mammalian central nervous system (CNS), and in peripheral tissues (Leurs et al., (1998), Trends Pharmacol. Sci. 19, 177-183). Activation of H3 receptors by selective agonists or histamine results in the inhibition of neurotransmitter release from a variety of different nerve populations, including histaminergic, adrenergic and cholinergic neurons (Schlicker et al., (1994), Fundam. Clin. Pharmacol. 8, 128-137). Additionally, in vitro and in vivo studies have shown that H3 antagonists can facilitate neurotransmitter release in brain areas such as the cerebral cortex and hippocampus, relevant to cognition (Onodera et al., (1998), In: The Histamine H3 receptor, ed Leurs and Timmerman, pp255-267, Elsevier Science B.V.). Moreover, a number of reports in the literature have demonstrated the cognitive enhancing properties of H3 antagonists (e.g. thioperamide, clobenpropit, ciproxifan and GT-2331) in rodent models including the five choice task, object recognition, elevated plus maze, acquisition of novel task and passive avoidance (Giovanni et al., (1999), Behav. Brain Res. 104, 147-155). These data suggest that novel H3 antagonists and/or inverse agonists such as the current series could be useful for the treatment of cognitive impairments in neurological diseases such as Alzheimer's disease and related neurodegenerative disorders.

The present invention provides, in a first aspect, a compound of formula (I):

$$(R^4)_r$$
 $(R^2)_n$
 $(CH_2)_m$
 $(R^3)_r$

wherein:

 R^1 represents hydrogen, $-C_{1-6}$ alkyl, $-C_{1-6}$ alkoxy, $-C_{3-8}$ cycloalkyl, $-C_{1-6}$ alkyl- $-C_{3-8}$ cycloalkyl, aryl, heterocyclyl, heterocyclyl, $-C_{1-6}$ alkyl-aryl, $-C_{1-6}$ alkyl-heteroaryl, $-C_{1-6}$ alkyl-aryl, $-C_{1-6}$ alkyl-heteroaryl, $-C_{1-6}$ alkyl-heteroaryl

heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, -heteroaryl, -heteroaryl, -heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heterocyclyl, -heterocyclyl-heterocyclyl, -heterocyclyl, -heterocyclyl, -heterocyclyl,

- wherein R¹ may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, COOR¹⁵, cyano, -C₁₋₆ alkyl-cyano, nitro, oxo, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C₁₋₆ alkyl (optionally substituted by a COOR¹⁵ group), C₂₋₆ alkynyl (optionally substituted by a COOR¹⁵ group), C₁₋₆ alkoxy (optionally substituted by a COOR¹⁵ group),
- pentafluoroethyl, C_{1-6} alkoxy, C_{2-6} alkenoxy, aryl, aryl C_{1-6} alkyl, -CO-aryl (optionally substituted by a halogen atom), -CO-heteroaryl, - C_{1-6} alkyl-CO-aryl, aryl C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl C_{1-6} alkyl,
- aryloxy, C₁₋₈ alkylsulfonamido, C₁₋₈ alkylamido, C₁₋₈ alkylsulfonamidoC₁₋₈ alkyl, C₁₋₈ alkylamidoC₁₋₈ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₈ alkyl, arylcarboxamidoC₁₋₈ alkyl, aroyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group -COR¹⁵, -NR¹⁵R¹⁶, -CONR¹⁵R¹⁶, -NR¹⁵COR¹⁶, -NR¹⁵SO₂R¹⁶ or -SO₂NR¹⁵R¹⁶, wherein R¹⁵ and R¹⁶ independently represent hydrogen, C₁₋₆ alkyl or C₃₋₈ cycloalkyl or together may be fused
- to form a 5- to 7- membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, C₁₋₆ alkyl or -C₁₋₆ alkylC₁₋₆ alkoxy group;

25 p is 1 or 2;

30

m, n and r independently represent 0, 1 or 2;

 R^2 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl, such that when n represents 2, two R^2 groups may instead be linked to form a phenyl ring; R^4 represents C_{1-6} alkyl, or when r represents 2, two R^4 groups may instead together form a bridged CH_2 , $(CH_2)_2$ or $(CH_2)_3$ group;

 R^{10} represents hydrogen or $C_{1-\theta}$ alkyl, or R^{10} , together with the nitrogen to which it is attached and R^1 forms a nitrogen containing heterocyclic group; R^3 represents - $(CH_2)_q$ -NR¹¹R¹² or a group of formula (i):

$$(CH_2)_f$$
 $(R^{14})_k$ (I)

35 wherein q is 2, 3 or 4;

R¹¹ and R¹² independently represent C₁₋₈ alkyl or C₃₋₈ cycloalkyl or together with the nitrogen atom to which they are attached represent an N-linked nitrogen containing heterocyclyl group optionally substituted by one or more R¹⁷ groups;

 R^{13} represents hydrogen, C_{1-6} alkyl, $-C_{1-6}$ alkyl- C_{1-6} alkoxy, C_{3-8} cycloalkyl, $-C_{1-6}$ alkyl-aryl or heterocyclyl;

- R^{14} and R^{17} independently represent halogen, C_{1-8} alkyl, haloalkyl, OH, di C_{1-8} alkylamino, C_{1-8} alkoxy or heterocyclyl;
- f and k independently represent 0, 1 or 2; g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0; with the proviso that when m represents 1, n and r both represent 0 and R³ represents – (CH₂)₃-N-piperidine or –(CH₂)₃-N(ethyl)₂, R¹-Z represents a group other than methyl, -CO-O-C(CH₃)₃ or benzyl;
- and with the proviso that when m, n and r all represent 0, p represents 1, R³ represents (CH₂)₃-N-pyrrolidine or –(CH₂)₃-N-piperidine, R¹ represents benzyl, Z represents a group other than a bond;
 - and with the proviso that when m, n and r all represent 0, p represents 1, R^3 represents— $(CH_2)_3$ -N-piperidine, R^1 represents isopropyl, Z represents a group other than a bond;
- and with the proviso that when m represents 1, n and r both represent 0, p represents 1, R³ represents—(CH₂)₃-N-piperidine, R¹ represents methyl, isopropyl, aryl or benzyl, Z represents a group other than a bond; and with the proviso that when m and n both represent 0, R³ represents—(CH₂)₃-
- N(ethyl)₂, p represents 1, r represents 2 and R¹ and R⁴ both represent methyl, Z represents a group other than a bond;

or a pharmaceutically acceptable salt thereof.

In one particular aspect of the present invention, there is provided a compound of formula (I) as defined above wherein:

- R¹ represents a group other than hydrogen, -C₁₋₈ alkoxy or -C₁₋₈ alkyl-C₃₋₈ cycloalkyl; and R¹ is optionally substituted by one or more substituents other than COOR¹⁵, -C₁₋₈ alkyl-cyano, C₁₋₈ alkyl substituted by a COOR¹⁵ group), C₂₋₆ alkenyl (optionally substituted by a COOR¹⁵ group), C₁₋₈ alkynyl (optionally substituted by a COOR¹⁵ group), C₁₋₈ alkoxy (optionally substituted by a COOR¹⁵ group), C₂₋₆ alkenoxy, aryl, arylC₁₋₈ alkyl, -CO-aryl
- 30 (optionally substituted by a halogen atom), -CO-heteroaryl, - C_{1-6} alkyl-CO-aryl or C_{3-7} cycloalkyl; and
 - R¹⁵ and R¹⁶ independently represent a group other than C₃₋₈ cycloalkyl or together may be fused to form an unsubstituted 5- to 7- membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom; and
- r represents 0; and two R² groups are not linked to form a phenyl ring; and R¹¹ and R¹² independently represent a group other than C₃₋₈ cycloalkyl; and R¹³ represents a group other than -C₁₋₈ alkyl-C₃₋₈ cycloalkyl.
- In a second particular aspect of the present invention, there is provided a compound of formula (I) as defined above wherein m represents 0 or 2.

In a further particular aspect of the present invention, there is provided a compound of formula (I) as defined above wherein Z represents CO, CONR¹⁰ or SO₂.

Alkyl groups, whether alone or as part of another group, may be straight chain or branched and the groups alkoxy and alkanoyl shall be interpreted similarly. Alkyl moieties are more preferably C₁₋₄ alkyl, eg. methyl or ethyl. The term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.

The term "aryl" includes single and fused rings wherein at least one ring is aromatic, for example, phenyl, naphthyl, tetrahydronaphthalenyl, indanyl or fluorenyl.

The term "heterocyclyl" is intended to mean a 4-7 membered monocyclic saturated or partially unsaturated ring or a 4-7 membered saturated or partially unsaturated ring fused to a benzene ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur. Suitable examples of such monocyclic rings include pyrrolldinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, diazepanyl, azepanyl and azocanyl. Suitable examples of benzofused heterocyclic rings include indolinyl, isoindolinyl, benzodioxolyl and dihydroisogulnolinyl.

20

15

The term "nitrogen containing heterocyclyl" is intended to represent any heterocyclyl group as defined above which contains a nitrogen atom.

- The term "heteroaryl" is intended to mean a 5-7 membered monocyclic aromatic or a fused 8-11 membered bicyclic aromatic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur. Suitable examples of such monocyclic aromatic rings include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl and pyridyl. Suitable examples of such fused aromatic rings include furopyridinyl and benzofused aromatic rings such as quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, indolyl, indazolyl, pyrrolopyridinyl, benzofuranyl, benzothianyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and the like.
 - 35 Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for and are antagonists and/or inverse agonists of the histamine H3 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive dysfunction, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson's disease, multiple sclerosis, stroke and sleep disorders including narcolepsy; psychlatric disorders including schizophrenia, attention deficit hypereactivity disorder, depression and addiction; and other diseases including obesity, asthma,

alkenyl (eg. ethenyl) optionally substituted by COOR¹⁵ (eg. COOMe); C₃₋₇ cycloalkyl (eg. cyclopentyl); C₁₋₆ alkylsulfonyl (eg. –SO₂Me); C₁₋₆ alkenoxy (eg. –OCH₂CH=CH₂); C₁₋₆ alkylthio (eg. –S-ethyl); NR¹⁵R¹⁶ (eg. N(Me)₂); -C₁₋₆ alkyl-aryl (eg. benzyl); aryl (eg. phenyl); -CO-aryl (eg. –CO-phenyl) optionally substituted by halogen (eg. chlorine); -CO-heteroaryl (eg. –CO-azetidinyl); -CO-heterocyclyl (eg. –CO-tetrahydropyranyl); -COOR¹⁵ (eg. COOH, COOMe or COOt-butyl); -COR¹⁵ (eg. –CO-methyl, -CO-ethyl, -CO-isopropyl, -CO-cyclopropyl, -CO-cyclopentyl or -CO-cyclohexyl); -CONR¹⁵R¹⁶ (eg. –CONH₂, -CO-pyrrolidinyl, -CO-morpholinyl, -CO-piperazinyl, -CO-piperidinyl, -CO-thiomorpholinyl) optionally substituted by C₁₋₆ alkyl (eg. methyl), halogen (eg. fluorine) or -C₁₋₆ alkylC₁₋₆ alkoxy (eg. –CH₂-OMe); or -C₁₋₆ alkyl-CO-aryl (eg. –CH₂COphenyl) groups.

More preferably, R¹ is optionally substituted by one or more (eg. 1, 2 or 3): halogen (eg. fluorine); oxo; cyano; -CONR¹⁵R¹⁶ (eg. -CO-pyrrolidinyl) or -COR¹⁵ (eg. -CO-isopropyl, -CO-cyclopropyl or -CO-cyclobutyl).

Preferably, Z represents a bond, CO or CONR¹⁰. More preferably, Z represents bond or CO, especially CO.

Preferably, R¹⁰ represents hydrogen or C₁₋₆ alkyl.

20 Preferably, m is 0 or 2, more preferably 0.

Preferably, n is 0 or 1, more preferably n is 0.

When n represents 1, R^2 is preferably halogen (eg. chlorine, bromine or fluorine), trifluoromethyl, cyano or C_{1-6} alkyl (eg. methyl). Preferably, r is 0.

When r represents 1 or 2, R² is preferably C₁₋₈ alkyl (eg. methyl) or two R⁴ groups together form a bridged CH₂ group.

Preferably, p is 1.

15

Preferably, R³ represents -(CH₂)_q-NR¹¹R¹².

When R³ represents a group of formula (i), preferably f is 0 or 1, g is 2, h is 1, k is 0 and R¹³ represents hydrogen, optionally substituted C₁₆ alkyl (eg. ethyl, methylpropyl, isopropyl or methoxyethyl), C₃₊₆ cycloalkyl (eg. cyclopropyl, cyclobutyl or cyclopentyl) or - C₁₊₆ alkyl-C₃₊₆ cycloalkyl (eg. -CH₂-cyclopropyl).

When R³ represents a group of formula (i), more preferably f is 0, g is 2, h is 1, k is 0 and R¹³ represents C₁₊₆ alkyl (eg. isopropyl) or C₃₊₆ cycloalkyl (eg. cyclopropyl or cyclobutyl).

- Preferably, q is 2 or 3, more preferably 3.

 Preferably, R¹¹ and R¹² independently represent C₁₋₆ alkyl (eg. methyl) or C₃₋₈ cycloalkyl (eg. cyclopentyl) or NR¹¹R¹² represents a heterocyclic group (eg. piperidinyl, pyrrolidinyl, thiomorpholinyl, azepanyl or azocanyl optionally substituted by one or more halogen (eg. fluorine) or C₁₋₆ alkyl (eg. methyl or ethyl).
- 40 More preferably NR¹¹R¹² represents pyrrolidinyl, piperidinyl, azepanyl or azocanyl optionally substituted by one or more C_{1.6} alkyl (eg. methyl or ethyl), especially unsubstituted piperidine.

Preferably, -O-R³ is present at the para position of the phenyl group with respect to the rest of the compound.

Preferred compounds according to the invention include examples E1-E503 as shown below, or a pharmaceutically acceptable salt thereof.

Compounds of formula (I) may form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, sulphuric, citric, lactic, mandelic, tartaric and methanesulphonic. Salts, solvates and hydrates of compounds of formula (I) therefore form an aspect of the invention.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of these compounds and the mixtures thereof including racemates. Tautomers also form an aspect of the invention. For example, when R³ represents (CH₂)_qNR¹¹R¹² and NR¹¹R¹² represents a nitrogen containing heterocyclyl group substituted by one or more C₁₋₈ alkyl groups it will be appreciated that the present invention extends to cover diastereomeric and enantiomeric compounds.

20

5

10

15

The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)

25

$$(R^4)_r$$
 $(R^2)_n$
 $(CH_2)_m$
 (II)

wherein R¹, Z, R⁴, p, m, r, R² and n are as defined above, with a compound of formula R³-L¹, wherein R³ is as defined above for R³ or a group convertible thereto and L¹ represents a suitable leaving group such as a halogen atom (eg. bromine or chlorine) or an optionally activated hydroxyl group; or

(b) preparing a compound of formula (I) wherein Z represents CO by reacting a compound of formula (III)

35

30

$$(R^4)_r$$
 $(R^2)_n$
 $(CH_2)_m$
 $O \longrightarrow R^3$

or a protected derivative thereof, wherein R⁴, r, p, m, R², n and R³ are as defined above, with a compound of formula R¹-COX, wherein R¹ is as defined above and X represents a suitable leaving group such as an activated hydroxy group, a suitable halogen atom or benzotriazolyl; or

- (c) preparing a compound of formula (I) wherein Z represents SO₂ by reacting a compound of formula (III) as defined above with a compound of formula R¹-SO₂Cl, wherein R¹ is as defined above; or
- (d) preparing a compound of formula (I) wherein Z represents NR¹ºCO by reacting a compound of formula (III) as defined above with a compound of formula R¹-N≡C≡O, wherein R¹ is as defined above; or
- (e) preparing a compound of formula (I) wherein Z represents CONR¹⁰ by reacting a compound of formula (III) as defined above, sequentially with phosgene in a solvent such as toluene followed by a compound of formula R¹⁰R¹-NH, in a solvent such as dichloromethane, wherein R¹ and R¹⁰ are as defined above; or
- (f) preparing a compound of formula (I) wherein m represents 1 by reacting a compound of formula (IV)

(IV)

with a compound of formula (XI)

10

15

20

25

$$(R^4)_r$$
 (XI)

or an optionally protected derivative thereof, wherein R⁴, r, R², n, R³, R¹, Z and p are as defined above under reducing conditions; or

- (g) deprotecting a compound of formula (I) which is protected; and
- (h) interconversion to other compounds of formula (l).

5

When R^3 represents - $(CH_2)_q$ - $NR^{11}R^{12}$, process (a) typically comprises the use of a suitable base, such as potassium carbonate in an appropriate solvent such as 2-butanone optionally in the presence of an activating reagent such as potassium iodide at an appropriate temperature such as reflux.

10

When a group $R^{3'}$ convertible to R^3 represents, for example, L^2 -(CH_2) $_q$ -, process (a) typically comprises an alkylation reaction using analogous conditions to those described above.

When R³ represents a group of formula (i) and L¹ represents an optionally activated hydroxyl group, process (a) typically comprises the use of a phosphine such as triphenylphosphine in a suitable solvent such as tetrahydrofuran, followed by addition of an azodicarboxylate such as diethylazodicarboxylate at a suitable temperature such as room temperature.

20

Process (b) typically comprises the use of an appropriate solvent such as dichloromethane optionally in the presence of an organic or inorganic base such as potassium carbonate or in the presence of a suitable coupling agent such as 1,3-dicyclohexylcarbodiimide and 1-hydroxybenzotriazole.

25

Processes (c) and (d) typically comprise the use of a suitable solvent such as 2-butanone.

Process (e) typically comprises the use of a suitable base, such as triethylamine.

30

Process (f) comprises the use of reductive conditions (such as treatment with a borohydride eg. sodium triacetoxyborohydride), optionally in the presence of an acid, such as acetic acid, followed by optional deprotection in the event that the compound of formula (XI) is a protected derivative.

35

40

In process (g), examples of protecting groups and the means for their removal can be found in T. W. Greene 'Protective Groups in Organic Synthesis' (J. Wiley and Sons, 1991). Suitable amine protecting groups include sulphonyl (e.g. tosyl), acyl (e.g. acetyl, 2',2',2'-trichloroethoxycarbonyl, benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane) or reductively (e.g. hydrogenolysis of a benzyl group or reductive removal of a 2',2',2'-

trichloroethoxycarbonyl group using zinc in acetic acid) as appropriate. Other suitable amine protecting groups include trifluoroacetyl (-COCF₃) which may be removed by base catalysed hydrolysis or a solid phase resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman linker), which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic acid.

Process (h) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis or amide bond formation. For example, compounds of formula (I) wherein R³ represents a group of formula (i) may be interconverted at the R¹³ position by reaction with an alkyl halide such as 1-chloro-2-methoxyethane in the presence of a base such as potassium carbonate in a suitable solvent such as 2-butanone optionally in the presence of a transfer reagent such as potassium iodide. Such interconversion may also be carried out by reductive amination, for example, with acetone in the presence of a borohydride such as sodium triacetoxyborohydride and optionally an acid such as acetic acid in a suitable solvent such as dichloromethane.

Compounds of formula (II) and (III) wherein m is 1 or 2 may be prepared in accordance with the following scheme:

$$(IV) \qquad (R^{2})_{n} \qquad H \qquad (R^{2})_{n} \qquad (R^$$

20

10

15

wherein R^4 , r, R^2 , n, R^3 , p are as defined above and the compound of formula (V) may be optionally protected.

25 Step (i) may be performed in an analogous manner to that described for process (f) above.

Compounds of formula (III) wherein m is 0 may be prepared in accordance with the following scheme:

H

$$(R^4)$$
 $(R^2)_n$
 $(R^2)_n$

wherein R^4 , r, p, R^2 , n and R^3 are as defined above and P^1 represents a suitable protecting group (such as Boc).

- Step (i) may be performed when P¹ represents Boc by reacting a compound of formula (IX) with di-t-butyl carbonate in the presence of a suitable base (eg. triethylamine) in the presence of a suitable solvent (eg. dichloromethane) at a suitable temperature (eg. room temperature).
- Step (ii) may be performed in an analogous manner to the procedures shown below for the preparation of compounds of formula (IV).
 - Step (iii) typically comprises a deprotection reaction, for example, when P¹ represents Boc, deprotection may typically comprise reaction of a compound of formula (III)^{pl} with hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane.

15

Compounds of formula (III) wherein m is 2 may be prepared in accordance with the following scheme:

$$P^{2} \longrightarrow NH \qquad (XII)$$

$$(R^{4})_{r} \longrightarrow NH \qquad (R^{2})_{n} \qquad (R^{2})_{n}$$

$$(XIII)$$

$$(R^{4})_{r} \longrightarrow NH \qquad (R^{2})_{n} \qquad (R^{2})_{n}$$

$$(XIII)$$

$$(R^{4})_{r} \longrightarrow NH \qquad (R^{2})_{n} \qquad (R^{2})_{n}$$

$$(III)^{p}$$

$$(R^{4})_{r} \longrightarrow NH \qquad (R^{2})_{n} \qquad (R^{2})_{n}$$

$$(III)^{p}$$

wherein R², R³, R⁴, n, p, r are as defined above, P² represents a suitable protecting group such as Boc and L⁵ represents a suitable leaving group such as a halogen atom (eg. bromine).

Step (i) typically comprises reaction of a compound of formula (XII) with a compound of formula (XIII) in the presence of an inert solvent such as dimethylformamide or acetonitrile.

Step (ii) typically comprises a deprotection reaction, for example, when P² represents Boc, deprotection may typically comprise reaction of a compound of formula (III)^{pii} with hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane.

5

Compounds of formula (IV) wherein R³ represents -(CH₂)_q-NR¹¹R¹² may be prepared in accordance with the following scheme:

5

20

$$(R^{2})_{n}$$

$$(IV)^{a}$$

wherein R², n, q, R¹¹, R¹² are as defined above and L¹, L², L³ and L⁴ represent suitable leaving groups (eg. halogen atoms, such as bromine or chlorine).

Steps (i), (ii) and (iii) may be performed using similar conditions to those described for process (a) above.

Compounds of formula (IV) wherein R³ represents a group of formula (i) as defined above may be prepared in accordance with the following scheme:

$$(R^{2})_{n}$$

$$O - H$$

$$Step (i)$$

$$(VI)$$

$$(CH_{2})_{i}$$

$$(CH_{2})_{i}$$

$$(VII)$$

$$(VIII)$$

wherein R², n, f, g, h, k, are as defined above, L⁴ represents a suitable leaving group such as a halogen atom or a hydroxyl group and R^{13a} is as defined above for R¹³ or a protecting group such as t-butoxycarbonyl, followed by optional deprotection.

Step (i) may be performed using similar conditions to those described for process (a) above.

Compounds of formula (II) wherein m is 0 may be prepared by a deprotection reaction of a compound of formula (IX) as defined above, followed by an analogous process to

(2002)]. In vivo, H3 receptor agonists inhibit the decrease in nasal airway resistance produced by sympathetic nerve activation [Hey et al, Arzneim-Forsch Drug Res., 48:881-888 (1998)]. Furthermore, H3 receptor antagonists in combination with histamine H1 receptor antagonists reverse the effects of mast cell activation on nasal airway resistance and nasal cavity volume; an index of nasal congestion [McLeed et al, Am. J. Rhinol., 13: 391-399, (1999)]. A combined histamine H1 and H3 receptor antagonist, such as the series described herein, would be effective in the treatment of both the nasal congestion and the sneezing, itching and rhinorrhea associated with both seasonal and perennial allergic rhinitis.

10

15

25

Therefore, examples of disease states in which dual histamine H1 and H3 antagonists have potentially beneficial anti-inflammatory effects include diseases of the respiratory tract such as asthma (including allergic and non-allergic), allergic rhinitis, sinusitis, bronchitis (including chronic bronchitis), bronchiectasis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

Other examples of disease states in which dual histamine H1 and H3 antagonists have potentially beneficial effects include diseases of the gastrointestinal tract such as intestinal inflammatory diseases including inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis) and intestinal inflammatory diseases secondary to radiation exposure or allergen exposure.

Dual histamine H1 and H3 antagonists of the present invention may also be of use in the treatment of sleep/wake disorders, arousal/vigilance disorders, migraine, dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, Alzhelmer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, depression, manic disorders, bipolar disorders and diabetes.

Diseases of principal interest for a dual histamine H1 and H3 antagonist include asthma, COPD and inflammatory diseases of the upper respiratory tract involving seasonal and perennial allergic rhinitis, non-allergic rhinitis, and the specific symptoms associated with these diseases including nasal congestion, rhinorrhoea, sneezing, cough and itching (pruritis) of eyes, ears, nose and throat. Other diseases of principal interest include cough, chronic urticaria, allergic conjunctivitis, nasal polyposis, sinusitis, psoriasis, eczema and allergic dermatoses (including urticaria, atopic dermatitis, contact dermatitis, drug rashes and insect bites).

Diseases of principal interest include asthma, COPD, cognitive disorders and inflammatory diseases of the upper respiratory tract involving seasonal and perennial rhinitis.

Preferred diseases of principal interest include asthma, cognitive disorders and inflammatory diseases of the upper respiratory tract involving seasonal and perennial rhinitis.

Further diseases also of principal interest include inflammatory diseases of the gastrointestinal tract such as inflammatory bowel disease.

Thus the invention also provides a dual histamine H1 and H3 antagonist compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above disorders, in particular allergic

Preferred dual histamine H1 and H3 antagonist compounds of formula (I) are those wherein

R¹ represents aryl (eg. phenyl, naphthyl or tetrahydronaphthyl) or heteroaryl (eg.

15 benzofuranyl, indolyl or quinolinyl);

R¹ is optionally substituted by one or more (eg. 1, 2 or 3): halogen (eg. chlorine, fluorine or bromine); trifluoromethyl; -C₁₋₆ alkyl (eg. methyl, ethyl, isopropyl, propyl or t-butyl) optionally substituted by COOR¹⁵ (eg. COOEt); -C₁₋₆ alkoxy (eg. methoxy) optionally substituted by COOR¹⁵ (eg. COOMe); C₁₋₆ alkenyl (eg. ethenyl); NR¹⁵R¹⁶ (eg. N(Me)₂); or

20 C₁₋₆ alkylthio (eg. -S-ethyl) groups;

Z is a bond or CO;

m is 0 or 2;

n is 0;

r is 0;

25 p is 1.

10

R³ represents -(CH₂)₀-NR¹¹R¹²;

g represents 3; and

NR¹¹R¹² represents pyrrolidinyl, piperidinyl, azepanyl or azocanyl optionally substituted by one or more C₁₋₈ alkyl (eg. methyl or ethyl), more preferably piperidinyl substituted by one or two methyl or ethyl groups.

The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the above disorders.

40

30

35

When used in therapy, the compounds of formula (I) are usually formulated in a standard pharmaceutical composition. Such compositions can be prepared using standard procedures.

- Thus, the present invention further provides a pharmaceutical composition for use in the treatment of the above disorders which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- The present invention further provides a pharmaceutical composition which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- The pharmaceutical compositions according to the invention may also be used in combination with other therapeutic agents, for example anti-inflammatory agents (such as corticosteroids (e.g. fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide) or NSAIDs (eg. sodium cromoglycate, nedocromil sodium, PDE-4 inhibitors, leukotriene antagonists, lipoxygenase inhibitors, chemokine antagonists (e.g CCR3, CCR1, CCR2, CXCR1,
- CXCR2), iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a agonists)) or beta adrenergic agents (such as salmeterol, salbutamol, formoterol, fenoterol or terbutaline and salts thereof), or sympathomimetics (e.g pseudoephedrine or oxymetazoline), or other antagonists at the histamine receptor (e.g H4), or cholinesterase inhibitors, or cholinergic antagonists, or antiinfective agents (eg. antibiotics, antivirals).

A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, topical, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

30

35

PATRICULAR SERVICE CONTRACTOR CON

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents,

PCT/EP2003/011423 WO 2004/035556

non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.

The following Descriptions and Examples illustrate the preparation of compounds of the invention.

30 **Description 1**

10

15

20

25

35

40

4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-piperazine-1-carboxylic acid tert -butyl ester (D1)

To a solution of 4-(3-(piperidin-1-yl)propoxy)benzaldehyde (WO 02/12214 A2) (1.90g, 7.68mmol) in dichloromethane (25ml) was added 1-N tert butoxy carbonyl piperazine (1.57g, 8.45mmol) followed by acetic acid (1ml), and the reaction stirred for 1 hour at room temperature, then treated with sodium triacetoxy borohydride (2g, 9.61mmol) and stirred for 16 hours at room temperature. The reaction was then diluted with saturated sodium bicarbonate solution and extracted with dichloromethane. The dichloromethane was then washed sequentially with water and brine, dried over anhydrous sodium sulfate and evaporated in vacuo to yield a residue which was purified using silica gel chromatography eluting with a mixture of 0.880 ammonia:methanol:dichloromethane (0.5:4.5:95) to afford the title compound (1.586g, 50%); MS (ES+), m/e 418 [M+H]⁺.

Description 2

1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-piperazine trihydrochloride (D2)

To a solution of 4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-piperazine-1-carboxylic acid tert-butyl ester (D1) (1.576g, 3.76mmol) in a (1:1) mixture of dichloromethane and methanol (20ml) was added a 1M solution of hydrogen chloride in diethyl ether (20ml) and the reaction stirred for 5 hours at room temperature. The solvent was then evaporated *in vacuo* and the resulting residue triturated with diethyl ether to afford the title compound (1.5g, 93%); MS (ES+), m/e 318 [M+H]⁺.

10

Description 3

4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]dlazepane-1-carboxylic acid *tert*-butyl




The title compound (D3) was prepared from [1,4]diazepane-1-carboxylic acid *tert*-butyl ester using the method of Description 1 (D1).

MS(ES+) m/e 432 [M+H]⁺.

Description 4

20 1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4)



4-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane-1-carboxylic acid *tert*-butyl ester (D3) (2.27g, 5.27mmol) was dissolved in dichloromethane (10ml), treated with trifluoroacetic acid (5ml) and stirred at room temperature under argon for 2 hours. The solvent was removed *in vacuo* and the residue dissolved in methanol and passed down an SCX column (10g) eluting with methanol followed by 0.88 ammonia/methanol (1:9). The basic fractions were combined and concentrated *in vacuo* to afford the title compound (1.57g).

MS(ES+) m/e 332 [M+H]⁺.

14

25

30

Description 5

4-(4-Formyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester (D5)

4-Hydroxybenzaldehyde (2.0g, 16.4mmol) was dissolved in tetrahydrofuran (20ml) and treated with 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (4.1g, 20.5mmol) and

by column chromatography on silica eluting with 4-1 hexane – ethyl acetate to afford the title compound as a colourless viscous oil (3.8 g) MS (ES+) m/e 355 [M+H]⁺.

5 Description 10

4-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D10)

A mixture of 4-[4-(3-chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D9) (4.0 g; 11.3 mM), piperidine (2.23 ml; 2 eq), potassium carbonate (3.73 g; 2.4 eq)

and potassium iodide (3.74 g; 2 eq) in butan-2-one (100 ml) was heated at reflux for 3 days. The mixture was allowed to cool to room temperature, filtered and evaporated to give the title compound as a pale yellow solid (4.6 g)

MS (ES+) m/e 404 [M+H]⁺.

15 Description 11

20

1-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine (D11)

A solution of 4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D10) (1.0 g; 2.48 mM) in trifluoroacetic acid (5 ml) was stirred at room temperature for 60 minutes. The resulting mixture was purified on an SCX ion exchange cartridge to afford the title compound as a colourless crystalline solid (0.76 g) MS (ES+) m/e 304 [M+H]⁺.

Description 12

4-(3-Hydroxy-phenyl)-piperazine-1-carboxyllc acid tert-butyl ester (D12)

Prepared from 3-piperazin-1-yl-phenol (Chem. Pharm. Bull. <u>49</u>(10), 1314 (2001)) using the same method described in Description 8 (D8).

MS (ES+) m/e 279 [M+H]⁺.

Description 13

4-[3-(3-Chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D13)
Prepared from 4-(3-hydroxy-phenyl)-piperazine-1-carboxylic acid *tert*-butyl ester (D12)
using the same method described in Description 9 (D9).

MS (ES+) m/e 355 [M+H]⁺.

35 Description 14

4-[3-(3-Piperidin-1-yl-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D14)

Prepared from 4-[3-(3-chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (D13) using the same method described in Description 10 (D10).

40 MS (ES+) m/e 404 [M+H]+.

Description 15

1-[3-(3-PiperidIn-1-yl-propoxy)-phenyl]-piperazine (D15)

butyl ester (D14) using the same method described in Description 11 (D11).

MS (ES+) m/e 304 [M+H]⁺.

5

Description 16

4-Bromo-1-methyl-1H-indole (D16)



A solution of 4-bromo-1*H*-indole (6.7 g) in tetrahydrofuran (75 ml) was treated with sodium hydride (1.24 g) and stirred for 0.5 h at room temperature. The resulting suspension was treated with a solution of iodomethane (2.34 ml) in tetrahydrofuran (35 ml) at 0°C and allowed to warm to room temperature over 1h, whilst stirring. The reaction mixture was poured onto water and partitioned between dichloromethane and water. The organic phase was dried over (MgSO₄) and concentrated in vacuo to afford the title compound (7.2 g). TLC Silica (cyclohexane-ethyl acetate [1:1]), Rf = 0.55.

Description 17

4-Bromo-1-methyl-1H-indole-3-carboxylic acid (D17)

A solution of 4-bromo-1-methyl-1*H*-indole (D16) (7.0 g) in tetrahydrofuran (50 ml) was treated with a solution of trifluoroacetic anhydride (5.65 ml) in tetrahydrofuran (20 ml) at 0°C. The reaction mixture was allowed to warm to room temperature over 6 h, whilst stirring. The reaction mixture was concentrated *in vacuo* and then re-suspended in ethanol (25 ml). The solution was treated with 5N sodium hydroxide solution (50 ml) and heated under reflux for 18 h. The reaction mixture was washed with diethyl ether and the aqueous phase acidified with 5N hydrochloric acid solution. The precipitate was filtered, washed with water and concentrated *in vacuo* to afford *the title compound* (4.88 g). TLC, Silica (cyclohexane-ethyl acetate-acetic acid [3:1:0.1]), Rf = 0.35.

30 Descriptions 18-23

Descriptions 18-23 were prepared using analogous methods to Example 76b by substituting 2-methylpiperidine with the appropriate amine.

1			
Description	Churchung	1	
Description	Structure	RT (min)	Mass Ion (M+H) ⁺
			111400 1011 (1811)

	18		1.64	332
	19	CH, SH	0.65	304
ng dan katalang ng katalang da sakang katalang katalang katalang	20	HO	1.77	346
	21	CH ₃	1.45	318
no construire de proposition de la construire de la const	22	H ₃ C N N N N N N N N N N N N N N N N N N N	1.57	332
	23	H ₄ C NH	1.61	318

Descriptions 24-32

Descriptions 24-32 were prepared by analogous methods to those indicated in the below table:

5

	Description	Name	Prepared analogously to	RT (min)
TO STATE OF THE ST	24	1,1-Dimethylethyl 4-(2-naphthalenyl)- 1-piperazinecarboxylate	E229a from known starting materials	3.74
	25	1,1-Dimethylethyl 4-(4-quinolinyl)-1- piperazinecarboxylate and 1,1- dimethylethyl 4-(3-quinolinyl)-1- piperazinecarboxylate (1:1)	E229a from known starting materials	2.18 & 3.02

26	1-(2-Naphthalenyl)piperazine	E229b from known	2.00
		starting materials	
27	4-(1-Piperazinyl)quinoline and 3-(1-piperazinyl)quinoline (1:1)	E229b from D25	1.18
28	3-{[4-(2-Naphthalenyl)-1- piperazinyl]methyl}phenol	E229c from D24	2.39
29	3-{[4-(1-Naphthalenyl)-1- piperazinyl]methyl}phenol	E229c from D26	2.41
30	4-{[4-(8-Quinolinyl)-1- piperazinyl]methyl}phenol	E229c from E229b	1.78
31 Nation insolution	4-{[4-(4-Quinolinyl)-1- piperazinyl]methyl}phenol and 3-{[4-(3-quinolinyl)-1- piperazinyl]methyl}phenol (1:1)	E229c from D27	1.91
32	4-{[4-(1-Naphthalenyl)-1-piperazinyl]methyl}phenol	E229c from D26	2.46

Descriptions 33-42

Descriptions 33-42 were prepared by analogous methods to those indicated in the below table:

5

	Description	Name	Prepared analogously to	RT (min)
de en sindre de servicio de la companya de la comp	33	2-Methyl-4-[4-(2-{4- [(phenylmethyl)oxy]phenyl}ethyl)-1- piperazinyl]quinoline	E237a from known starting materials	2.20
	34	2-Methyl-4-[4-(2-{3- [(phenylmethyl)oxy]phenyl}ethyl)-1- piperazinyl]quinoline	E237a from known starting materials	2.11
	35	1-(1-Naphthalenyl)-4-(2-{4- [(phenylmethyl)oxy]phenyl}ethyl) piperazine	E237a from known starting materials	2.91
	36	1-(1-Naphthalenyl)-4-(2-{3- [(phenylmethyl)oxy]phenyl}ethyl) piperazine	E237a from known starting materials	2.82

37	1-Phenyl-4-(2-{4- [(phenylmethyl)oxy]phenyl}ethyl) piperazine	E237a from known starting materials	2.55
	4-{2-[4-(2-Methyl-4-quinolinyl)-1-	E237b from	1.69
39	3-(2-[4-(2-Methyl-4-quinolinyl)-1- piperazinyl]ethyl}phenol	E237b from D34	4.56
40	4-{2-[4-(1-Naphthalenyl)-1- piperazinyl]ethyl}phenol	E237b from D35	2.28
41	3-{2-[4-(1-Naphthalenyl)-1- piperazinyl]ethyl}phenol	E237b from D36	2.32
42	4-[2-(4-Phenyl-1- piperazinyl)ethyl]phenol	E237b from D37	2.02

Description 43

3-Bromo-4-ethyl-benzoic acid (D43)



To a mixture of conc. HNO₃ (66 mL), glacial AcOH (300 mL) and water (50 mL), 4-ethylbenzoic acid (15 g) was added, stirring vigorously, before treating with bromine (5.67 mL). Finally a solution of AgNO₃ (16.97 g) in water (50 mL) was added dropwise and the mixture was stirred vigorously for 2 h. The precipitate was collected by filtration, washed well with water, before being extracted with hot, saturated K₂CO₃ solution, and then treated with charcoal. The hot solution was filtered through kieselguhr and the solution was acidified to pH1 using conc. HCl. The resulting white precipitate was collected by filtration and dried in the vacuum oven overnight at 60 °C to afford the title compound (19.46 g).

NMR (CDCl₃) δ 1.26 (3H, t), 2.83 (2H, q), 7.34 (1H, d), 7.97 (1H, dd), 8.27 (1H, dd)

Description 44

15

20

Methyl 3-bromo-4-ethyl-benzoate (D44)



3-Bromo-4-ethyl-benzoic acid (D43) (19.40 g) was dissolved in MeOH (200 mL) and then treated with conc. H₂SO₄ (1 mL). The mixture was heated at reflux overnight, and then concentrated under reduced pressure. The residue was partitioned between EtOAc and saturated aqueous NaHCO₃ solution, extracting again with EtOAc. The combined

extracts were then washed with brine, dried (MgSO₄). The solvent was evaporated in vacuo to afford the title compound (15.8 g). ¹H NMR (CDCl₃) δ 1.24 (3H, t), 2.79 (2H, q), 3.91 (3H, s), 7.29 (1H, d), 7.89 (1H, dd), 8.19 (1H, d).

Description 45

10

15

Methyl 3-cyano-4-ethyl-benzoate (D45)

Methyl-3-bromo-4-ethyl-benzoate (D44) (5-g) in NMP (180 mL) was treated with copper (I) cyanide (3.69 g). The mixture was then heated at reflux for 5 h, under argon. After cooling to 20 °C the reaction mixture was diluted with water, then filtered through kieselguhr, washing well with water and EtOAc. The organic layer was washed with water, brine and dried over MgSO₄. The solvent was evaporated to dryness in vacuo and the residue was purified by chromatography on silica eluting with EtOAc- Hexane (1:9) to give the title compound (1.9 g) ¹H NMR (CDCl₃) δ 1.33 (3H, t), 2.94 (2H, q), 3.94 (3H, s), 7.43 (1H, d), 8.17 (1H, dd), 8.28 (1H, d).

Description 46

3-Cyano-4-ethyl benzoic acid (D46)

Methyl 3-cyano-4-ethyl-benzoate (D45) (1.92 g) was dissolved in MeOH (50 mL) before adding 1M NaOH solution (15.24 mL) and stirring the resulting mixture overnight at room temperature, under argon. The reaction mixture was diluted with water, and extracted with EtOAc. The aqueous layer was acidified to pH1 using 2M HCl before extracting with EtOAc. The combined extracts were washed with brine, dried over MgSO4 and the 25 solvent evaporated to dryness in vacuo to afford the title compound (1.63 g). ¹H NMR (CDCl₃) δ 1.35 (3H, t), 2.97 (2H, q), 7.49 (1H, d), 8.24 (1H, dd), 8.36 (1H, d).

Analysis of the Examples was performed as follows:

LCMS was conducted on a Supelcosil LCABZ+PLUS column (3.3 cm x 4.6 mm ID) 30 eluting with 0.1% formic acid and 0.01M ammonium acetate in water (solvent A) and 0.05% formic acid and 5% water in acetonitrile (solvent B), using the following elution gradient 0.0-7min 0%B, 0.7-4.2 min 100%B, 4.2-5.3 min 0%B, 5.3-5.5min 0%B at a flow rate of 3 mL/min. The mass spectra were recorded on a Fisons VG Platform spectrometer using electrospray positive and negative mode (ES+ve and ES-ve).

_			
	methanone (E3)		
	1-(3,5-Dichloro-phenyl)-1-{4-[4-(3-	3,5-	MS (ES+) m/e
	piperidin-1-yl-propoxy)-benzyl]-piperazin-1-	dichlorobenzoic	491/493 [M+H]+
	yl}-methanone (E4)	acid	
	1-(4-Bromo-3-methyl-phenyl)-1-{4-[4-(3-	3-methyl, 4-bromo	MS (ES+) m/e
	piperidin-1-yl-propoxy)-benzyl]-piperazin-1-	benzoic acid	515/517 [M+H] ⁺
χ.	yl}-methanone (E5)		
	1-(2-Methoxy-phenyl)-1-{4-[4-(3-piperidin-	2-methoxy benzoic	MS (ES+) m/e
LE CONTRATAR PROPERTIES NA CONTRATA DE SONO PROPERTIES DE LA CONTRATA DE LA CONTRATA DE LA CONTRATA DE LA CONT	.1-yl-propoxy)-benzyl]-piperazin-1-yl}-	.acid	452 [M±H]+
	methanone (E6)		
	1-(3,4-Dichloro-phenyl)-1-{4-[4-(3-	3,4-dichloro	MS (ES+) m/e
	piperidin-1-yl-propoxy)-benzyl]-piperazin-1-	benzoic acid	491/493/495
	yl}-methanone (E7)		[M+H] ⁺
	4-(1-{4-[4-(3-Piperidin-1-yl-propoxy)-	4-cyano benzoic	MS (ES+) m/e
	benzyl]-piperazin-1-yl}-methanoyl)-	acid	447 [M+H] ⁺
	benzonitrile (E8)		
	1-(4-Fluoro-phenyl)-1-{4-[4-(3-piperidin-1-	4-fluoro benzoic	MS (ES+) m/e
	yl-propoxy)-benzyl]-piperazin-1-yl}-	acid	440 [M+H]+
	methanone (E9)		
	1-(4-Bromo-phenyl)-1-{4-[4-(3-piperidin-1-	4-bromo benzoic	MS (ES+) m/e
	yl-propoxy)-benzyl]-piperazin-1-yl}-	acid	500/502 [M+H]+
į	methanone (E10)		
	1-Benzofuran-2-yl-1-{4-[4-(3-piperidin-1-yl-	2-benzofuran	MS (ES+) m/e
The control of the party and control of the control	propoxy)-benzyl]-piperazin-1-yl}-	carboxylic acid	462 [M+H]+
	methanone (E11)		

Example 12

1-Benzo[1,3]dioxol-5-yl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepan-1-yl}-methanone (E12)

5

1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4) (100mg, 0.30mmol) was dissolved in dichloromethane (5ml) and treated sequentially with benzo[1,3]dioxole-5-carboxylic acid (125mg, 0.75mmol), 1,3-dicyclohexylcarbodiimide (155mg, 0.75mmol) and 1-hydroxybenzotriazole hydrate (101mg, 0.75mmol). The mixture was allowed to stir at room temperature under argon for 12 hours, diluted with methanol and passed down an SCX ion exchange column (2g) eluting with methanol followed by 0.880

ammonia/methanol (1:9). The basic fractions were combined and concentrated *in vacuo* to afford the title compound (127mg). MS(ES+) *m/e* 480 [M+H]+.

Examples 13-15

5 Examples 13-15 (E13-E15) were prepared from Description 4 (D4) using an analogous method to that described in Example 12 (E12) by substituting benzo[1,3]dioxole-5-carboxylic acid for the appropriate acid indicated in the table.

Example	Carboxyllc acid	Mass Spectrum
1-Phenyl-1-{4-[4-(3-	Benzoic acid	MS(ES+) m/e 436
piperidin-1-yl-		[M+H] ⁺
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-	n.	
methanone (E13)		
1-Naphthalen-2-yl-1-	Naphthalene-2-	MS(ES+) m/e 486
{4-[4-(3-piperidin-1-yl-	carboxylic acid	[M+H] ⁺
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E14)		
1-(3,5-Dichloro-	3,5-Dichloro-benzoic	MS(ES+) m/e 505
phenyl)-1-{4-[4-(3-	acid	[M+H] ⁺
piperidin-1-yl-	'	
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E15)		

10 Examples 16-23

CONTRACTOR DESCRIPTION OF THE PROPERTY OF THE


Examples 16-23 (E16-E23) were prepared from Description 4 (D4) using an analogous method to that described in Example 12 (E12) by substituting benzo[1,3]dioxole-5-carboxylic acid for the appropriate acid indicated in the table followed by further purification by column chromatography on silica gel eluting with a mixture of .880

ammonia/methanol/dichloromethane (0.5:4.5:95).

Example	Carboxylic acid	Mass Spectrum
1-(4-Bromo-3-methyl-phenyl)-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-	4-Bromo-3-methyl- benzoic acid	MS(ES+) m/e 529 [M+H] ⁺
[1,4]diazepan-1-yl}- methanone (E16)		
1-(2-Methoxy-phenyl)-	2-Methoxy-benzoic	MS(ES+) m/e 466
1-{4-[4-(3-piperidin-1-	acid	[M+H] ⁺

<u></u>		
yl-propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E17)		
4-(1-{4-[4-(3-Piperidin-	4-Cyano-benzoic acid	MS(ES+) m/e 461
1-yl-propoxy)-benzyl]-		[M+H] ⁺
[1,4]diazepan-1-yl}-		
methanoŷl)-	år till fryskrige sykret en fry tokkriver en engelektriske til retilet om kykt eft	ma - 2006-1916, will be mit the mit - med a social in dispersion by a social section of the social section of
benzonitrile (E18)		
1-(4-Fluoro-phenyl)-1-	4-Fluoro-benzoic acid	MS(ES+) m/e 454
{4-[4-(3-piperidin-1-yl-		[M+H] ⁺
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-	·	
methanone (E19)		
1-(4-Bromo-phenyl)-1-	4-Bromo-benzoic acid	MS(ES+) m/e 515
{4-[4-(3-piperidin-1-yl-		[M+H] ⁺
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E20)		
1-Benzofuran-2-yl-1-	Benzofuran-2-	MS(ES+) m/e 476
{4-[4-(3-piperidin-1-yl-	carboxylic acid	[M+H] ⁺
propoxy)-benzyl]-		
[1,4]diazepan-1-yi}-	Ge EGE for god by the state of the first of the first of the section of the first o	the state point is bring in the control of the party of
methanone (E21)		
1-(3,4-Dichloro-	3,4-Dichloro-benzoic	MS(ES+) m/e 505
phenyl)-1-{4-[4-(3-	acid	[M+H] ⁺
piperidin-1-yl-		
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E22)		
1-Cyclopropyl-1-{4-[4-	Cyclopropane	MS(ES+) m/e 400
(3-piperidin-1-yl-	carboxylic acid	[M+H] ⁺
propoxy)-benzyl]-		
[1,4]diazepan-1-yl}-		
methanone (E23)		

Example 24 1-Cyclopentyl-1-{4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepan-1-yl}methanone (E24)



1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4) (100mg, 0.30mmol) was dissolved in dichloromethane (5ml), treated with cyclopentyl acid chloride (80mg, 0.60mmol), potassium carbonate (83mg, 0.60mmol) and allowed to stir at room
temperature under argon for 12 hours. The reaction mixture was diluted with methanol and passed down an SCX column (2g) eluting with methanol followed by ammonia/methanol (1:9). The basic fractions were combined and concentrated *in vacuo* to afford the title compound (56mg). MS(ES+) *m/e* 428 [M+H]⁺.

10 Example 25

1-Benzenesulfonyl-4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (E25)



1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-[1,4]diazepane (D4) (100mg, 0.30mmol) was dissolved in 2-butanone (5ml), treated with benzene sulfonyl chloride (57mg, 0.32mmol) and allowed to stir at room temperature under argon for 2 hours. The reaction mixture was diluted with methanol and passed down an SCX column (2g) eluting with methanol followed by ammonia/methanol (1:9). The basic fractions were combined and concentrated *in vacuo* to afford the title compound (91mg). MS(ES+) *m/e* 472 [M+H]⁺.

20

25

Examples 26-28 (E26-E28) were prepared from Description 4 (D4) using an analogous method to that described in Example 25 (E25) by substituting benzenesulfonyl chloride for the appropriate sulfonyl chloride indicated in the table.

Example	Sulfonyl Chloride	Mass Spectrum
1-(Naphthalene-2-sulfonyl)-4-[4-(3- piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepane (E26)	Naphthalene-2- sulfonyl chloride	MS(ES+) m/e 522 [M+H] ⁺
1-(4-Fluoro-benzenesulfonyl)-4-[4-(3-piperidin-1-yl-propoxy)-benzyl]- [1,4]diazepane (E27)	4-Fluoro- benzenesülfonyl chloride	MS(ES+) m/e 490 [M+H] ⁺
1-(4-Bromo-benzenesulfonyl)-4-[4-(3-piperidin-1-yl-propoxy)-benzyl]-	4-Bromo- benzenesulfonyl	MS(ES+) m/e 552 [M+H] ⁺

[1,4]diazepane (E28)	chloride	
[1,4]ulazeparie (Lzo)	CHOTICE	

Examples 29-31

Examples 29-31 (E29-E31) were prepared from Description 4 (D4) using an analogous method to that described in Example 25 (E25) by substituting benzenesulfonyl chloride

for the appropriate sulfonyl chloride indicated in the table followed by further purification by column chromatography on silica gel eluting with a mixture of .880 ammonia/methanol/dichloromethane (0.5:4.5:95).

Example	Sulfonyl Chloride	Mass Spectrum
1-(3,5-Dichloro-benzenesulfonyl)-	3,5-Dichloro-	MS(ES+) m/e 540
4-[4-(3-piperidin-1-yl-propoxy)-	benzenesulfonyl	[M+H] ⁺
benzyl]-[1,4]diazepane (E29)	chloride	
1-(3,4-Dichloro-benzenesulfonyl)-	3,4-Dichloro-	MS(ES+) m/e 540
4-[4-(3-piperidin-1-yl-propoxy)-	benzenesulfonyl	[M+H] ⁺
benzyl]-[1,4]diazepane (E30)	chloride	
4-{4-[4-(3-Piperidin-1-yl-propoxy)-	4-Cyano-	MS(ES+) m/e 497
benzyl]-[1,4]diazepane-1-	benzenesulfonyl	[M+H] [†]
sulfonyl}-benzonitrile (E31)	chloride	

10 Example 32

1-Phenyl-1-{4-[4-(piperidin-4-yloxy)-benzyl]-piperazin-1-yl}-methanone (E32)

The title compound (E32) was prepared from 4-{4-[4-(1-phenyl-methanoyl)-piperazin-1-ylmethyl]-phenoxy}-piperidine-1-carboxylic acid tert-butyl ester (D7) using the method described in Description 4 (D4). MS(ES+) m/e 380 [M+H]*.

Example 33


20 **(E33)**

The title compound (E33) was prepared from 1-phenyl-1-{4-[4-(piperidin-4-yloxy)-benzyl]-piperazin-1-yl}-methanone (E32) and acetone using the method described in Description 1 (D1). MS(ES+) m/e 422 [M+H]⁺.

5

Example 34

1-(4-{4-[1-(2-Methoxy-ethyl)-piperidin-4-yloxy]-benzyl}-piperazin-1-yl)-1-phenyl-methanone (E34)



10

25

PERSONAL PROPERTY AND ADDITIONAL PROPERTY OF A SECURIOR OF

1-Phenyl-1-{4-[4-(piperidin-4-yloxy)-benzyl]-piperazin-1-yl}-methanone (E32) (150mg, 0.40mmol) was dissolved in 2-butanone and treated with 1-chloro-2-methoxy-ethane (0.08ml, 0.80mmol), potassium carbonate (132mg, 0.96mmol) and potassium iodide (159mg, 0.96mmol). The reaction mixture was heated under reflux for 24 hours. The mixture was allowed to cool to room temperature, acidified by the addition of glacial acetic acid and passed down an SCX ion exchange column (2g) eluting with methanol followed by ammonia/methanol (1:9). The basic fractions were combined and

concentrated in vacuo to afford the title compound (76mg). MS(ES+) m/e 438 [M+H]⁺.

20 Examples 35-37

Examples 35-37 (E35-E37) were prepared in accordance with the following general synthesis:

The appropriate acid chloride (1.1 eq) was added to a mixture of 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (100 mg; 0.33 mM) and potassium carbonate (55 mg; 1.5 eq) in butan-2-one (2 ml). The resulting mixtures were stirred at room temperature for 3 hours and then purified on SCX ion exchange cartridges to afford the title compounds.

Example	Acid Chloride	Mass Spectrum
1-Cyclopropyl-1-{4-[4-(3-piperidin-	Cyclopropane	MS (ES+) m/e 372

1-yl-propoxy)-phenyl]-piperazin-1- yl}-methanone (E35)	carbonyl chloride	[M+H] ⁺ .
	Benzoyl-chloride	-MS (ES+) m/e 408 [M+H] ⁺ .
1-(3,4-Dichloro-phenyl)-1-{4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-methanone (E37)	3,4- Dichlorobenzoyl chloride	MS (ES+) m/e 477 [M+H] ⁺ .

Examples 38-39

TO PROGRESS OF THE PROGRESS OF THE PARTY OF

SERVICE PRODUCTION OF THE PROPERTY OF THE

CONTRACTOR PRODUCTION OF CONTRACTOR PROPERTY AND A ST

15

Examples 38-39 (E38-E39) were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same procedure as described in Examples 36 and 37, respectively.

Example	Mass Spectrum
1-Phenyl-1-{4-[3-(3-piperidin-1-yl-propoxy)-	MS (ES+) m/e 408 [M+H]+.
phenyl]-piperazin-1-yl)-methanone (E38)	
1-(3,4-Dichloro-phenyl)-1-(4-[3-(3-piperidin-1-yl-	MS (ES+) m/e 477 [M+H] [±]
propoxy)-phenyl]-piperazin-1-yl}-methanone	
(E39)	

Examples 40-42

Examples 40-42 (E40-E42) were prepared in accordance with the following general synthesis:

The appropriate sulphonyl chloride (1.1 eq) was added to a mixture of 1-[4-(3-piperidin-1-yi-propoxy)-phenyl]-piperazine (D11) (100 mg; 0.33 mM) and potassium carbonate (55 mg; 1.5 eq) in butan-2-one (2 ml). The resulting mixtures were stirred at room temperature for 3 hours and then purified on SCX ion exchange cartridges to afford the title compounds.

Example	Sulfonyl Chloride	Mass Spectrum
	Methane sulfonyl	MS (ES+) m/e 382.
propoxy)-phenyl]-piperazine (E40)	chloride	[M+H] ⁺ .
1-Benzenesulphonyl-4-[4-(3-piperidin-1-yl-	Benzene sulfonyl	MS (ES+) m/e 444
propoxy)-phenyl]-piperazine (E41)	chloride	[M+H] ⁺ .
1-(3,4-Dichloro benzenesulphonyl)-4-[4-(3-	3,4-	MS (ES+) m/e 513
piperidin-1-yl-propoxy)-phenyl]-piperazine	Dichlorobenzene	[M+H] ⁺ .
(E42)	sulfonyl chloride	

Examples 43-45

Examples 43-45 (E43-E45) were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same procedure as described in Examples 40, 41 and 42, respectively.

Example	Mass Spectrum
1-Methanesulphonyl-4-[3-(3-piperidin-1-yl-	MS (ES+) m/e 382
propoxy)-phenyl]-piperazine (E43)	[M+H] ⁺ .
1-Benzenesulphonyl-4-[3-(3-piperidin-1-yl-	MS (ES+) m/e 444
propoxy)-phenyl]-piperazine (E44)	[M+H] ⁺ .
1-(3,4-Dichloro benzenesulphonyl)-4-[3-(3-	MS (ES+) m/e 513
piperidin-1-yl-propoxy)-phenyl]-piperazine (E45)	[M+H] ⁺ .

5

and the second section of the second second

Examples 46-47

Examples 46-47 (E46-E47) were prepared in accordance with the following general synthesis:

The appropriate isocyanate (1.1 eq) was added to 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (100 mg; 0.33 mM) in butan-2-one (2 ml). The resulting mixtures were stirred at room temperature for 3 hours and then purified on SCX ion exchange cartridges to afford the title compounds.

Example	Isocyanate	Mass Spectrum
4-[4-(3-Piperidin-1-yl-propoxy)-	Isocyanatobenzene	MS (ES+) m/e
phenyl) piperazine-1-carboxylic acid	en et miger un garante jurge i Verni Straji, migeritär saj metri i i muse til se	423 [M+H]T.
phenylamide (E46)		
4-[4-(3-Piperidin-1-yl-propoxy)-	3,4-Dichloro	MS (ES+) m/e
phenyl] piperazine-1-carboxylic acid	isocyanato benzene	492 [M+H] ⁺ .
(3,4-dichloro-phenyl)-amide (E47)		

15

no construidad de la construidad de la

Example 48

4-[4-(3-PiperidIn-1-yl-propoxy)-phenyl] plperazlne-1-carboxylic acid cyclopropylamide (E48)

20

To a solution of 1-[4-(3-plpendin-1-yl-propoxy)-phenyl]-piperazine (DT1) (150 mg; 0.49 mM) in dry dichloromethane (3 ml) was added drop wise a 20% solution of phosgene in toluene (0.5 ml; ~2 eq) and the resulting mixture stirred for 1 hour. The solvent was

dichloromethane (4 ml). Triethylamine (0.14 ml; 2 eq) was added followed by cyclopropylamine (0.1 ml; 3 eq) and the mixture stirred for 18 hours. The solvent was removed by evaporation *in vacuo* and the residue purified on a silica column eluting with 3% methanol in dichloromethane to afford the title compound as a white solid (155 mg) MS (ES+) m/e 387 [M+H]⁺.

Examples 49-50

Examples 49-50 (E49-E50) were prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]piperazine (D15) using the same procedure as described in Examples 46 and 47,
respectively.

Example	Mass Spectrum
4-[3-(3-Piperidin-1-yl-propoxy)-phenyl]	MS (ES+) m/e 423
piperazine-1-carboxylic acid phenylamide (E49)	[M+H] ⁺ .
*4+[3=(3=Piperidin-1-yl-propoxy)-phenyl]	MS-(ES+) m/e-492
piperazine-1-carboxylic acid (3,4-dichloro-	[M+H] ⁺ .
phenyl)-amide (E50)	

Example 51

en telephone de la companie de la c

20

25

o podeo presidente en la como en esperante en altra en la como

15 1-(3,4-Dichloro-phenyl)-4-[4-(3-Piperidin-1-yl-propoxy)-phenyl] piperazine (E51)

Tris(dibenzylidineacetone) di palladium (0) (5 mol%; 23 mg) was added to a mixture of 1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D11) (150 mg; 0.49 mmol), 3,4-dichloro bromo benzene (160 mg; 1.2 eq), sodium *tert*-butoxide (71 mg; 1.1 eq) and racemic 2,2'-bis(diphenylphosphino)-1.1'-binaphthyl (7.5 mol%; 24 mg) in dry toluene (3ml). The resulting mixture was heated at reflux under argon for 18 hours. The reaction was allowed to cool to room temperature and diluted with ethyl acetate (10 ml). The resulting solids were removed by filtration and the filtrate evaporated *in vacuo*. The residue was purified by column chromatography on silica eluting with 3% methanol in dichloromethane to afford the title compound as a buff solid (45 mg) MS (ES+) m/e 448 [M+H]⁺.

Example 52

30 1-(3,4-Dichloro-phenyl)-4-[3-(3-Piperidin-1-yl-propoxy)-phenyl] piperazine (E52)

The title compound (E52) was prepared from 1-[3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazine (D15) using the same method as described in Example 51 (E51). MS (ES+) m/e 448 [M+H]⁺.

Example 53

Paramangangangangangangangangang<mark>. S</mark>a palanganat mengangangangangangangan ang labahangangan kanalag pang melabah

5-Fluoro-1-methyl-3-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}-1*H*-indole (E53)

A solution of 5-fluoro-1-methyl-1*H*-indole-3-carboxylic acid [WO 0071537 A1] (35 mg) and 1-(4-{[3-(1-plperidinyl)propyl]oxy}phenyl)piperazine (D11) (50 mg) in dichloromethane (1ml) was treated with benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (94.4 mg) and heated in a microwave (CEM[™] Discover microwave) at 120°C for 5 min. The reaction mixture was concentrated *in vacuo* and purified on a SCX cartridge (2g) eluting with methanol-aqueous ammonia (10:1) followed by mass directed auto preparative HPLC to give *the title compound* (12 mg). LCMS RT = 2.49 min, 478 (M+H)⁺

Examples 54-61

SECTION AND CONTRACTOR OF THE PROPERTY AND

THE STATE OF THE S

The following compounds were prepared in an analogous manner to the process described for E53 from D11 and a known appropriate acid, with the exception of Example 57 which was prepared from D11 and D17.

Example	Structure	RT (min)	Mass ion (M+H) ⁺
54		2.37	448 450
55	Note: Made and the state of the	2.26	464

	56		2.41	478
		CH COH		
	57		2.40	539 541
	F0	Cotto	0.00	474
	58		2.32	474
Filo como Religio (Cultado, principal de Partido de Partido (Cultado (Culta		ALLEN TO THE TOTAL STATE OF THE	ma, w parts of ma	. The transplace to be the first
	59		2.56	539 541
	60		2.54	546
		CH, CH, CH		
TO POINT PORTE CONTRACTOR OF THE POINT PORT OF THE POINT POINT POINT PORT OF THE POINT POI	ness out su to de servences		2:80	536
•		LOW LOW		
•			L	l

Example 62

(1-Methyl-3-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1-piperazinyl]carbonyl}-1*H*-indol-2-yl)acetic acid (E62)

Α solution of ethyl (1-methyl-3-{[4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)-1piperazinyl]carbonyl}-1H-indol-2-yl)acetate (E60) [54 mg] in methanol [6 ml] and water [0.8 ml] was treated with 2N sodium hydroxide [0.46 ml] and was heated under reflux for 2 h. The reaction mixture was quenched with hydrochloric acid [10 ml] at room temperature. The reaction mixture was concentrated in vacuo and partitioned between contracted in vacuo to give and water. The organic phase was dried and concentrated in vacuo to give the title compound (20 mg). LCMS RT = 2.35 min, 518 (M+H)*

Example 63

20

25

35

10 1-(1-Naphthoyl)-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine trifluoroacetate (E63)

E63a: 4-[4-(1-Naphthoyl)piperazin-1-yl]phenol

To a stirring mixture of 4-(1-piperazinyl)phenol (5.54 g) and triethylamine (10.83 ml) in dichloromethane (140 ml) was added dropwise, 1-naphthalenecarbonyl chloride (9.83 ml). The resulting reaction mixture was stirred under a nitrogen atmosphere for 3 h. The mixture was partitioned between dichloromethane and water and the organic phase was washed with saturated brine, dried (MgSO₄) and evaporated to dryness. The residue was suspended in 6:4 tetrahydrofuran-methanol (370 ml) and treated with a saturated solution of potassium carbonate in methanol (45 ml). The mixture was stirred at room temperature under a nitrogen atmosphere for 20 h. The solvent was evaporated and the residue was partitioned between dichloromethane and water. The organic phase was washed with saturated brine, dried (MgSO₄) and evaporated to give an oil (15.5 g), part of which (14.5 g) was purified by chromatography on a silica SPE bond elut cartridge eluting with 10% -80% ethyl acetate - cyclohexane gradient to give the title compound (8.9g). LCMS RT = 2.97 min.

E63b: 1-[4-(3-Chloropropoxy)phenyl]-4-(1-naphthoyl)piperazine

Was prepared from 4-[4-(1-naphthoyl)piperazin-1-yl]phenol (E63a) and 1-bromo-3-30 chloropropane using the same method described in Description 9 LCMS RT = 3.59 min

E63c: 1-(1-Naphthoyl)-4-[4-(3-piperidin-1-ylpropoxy)phenyl]piperazine trifluoroacetate

1-[4-(3-Chloropropoxy)phenyl]-4-(1-naphthoyl)piperazine (E63b) (27 mg) piperidine (0.033 ml), potassium carbonate (46 mg), potassium iodide (56 mg)in 2-butanone (2 ml) was heated to reflux for 36 h. The solvent was removed at room temperature by a stream of nitrogen gas. The residue was dissolved in water and dichloromethane. The organic layer was separated, concentrated and purified by mass directed preparative HPLC to give the title compound (23 mg). LCMS RT = 2.15 min, ES+ve m/z 458 (M+H)*.

Examples 64-75

Examples 64-75 were prepared in an array format using the same method described in Example 63c from 1-[4-(3-chloropropoxy)phenyl]-4-(1-naphthoyl)piperazine (0.067 mmol), the appropriate secondary amine (5.0 eq), potassium carbonate (5.0 eq), and potassium iodide (5.0 eq) in 2-butanone (2 ml). The products were purified by mass directed auto-preparative HPLC to provide the compounds as TFA salts.

_	

	Example	Structure	RT	Mass
TO PROPERTY SECURE AND CONTRACTOR OF THE PROPERTY OF THE PROPE	All of his area and a	NATION FOR THE STORMER WITH WARREN EXPERIENCE WARREN WITH THE PROPERTY OF WITHOUT AND WARREN WARREN WAS A STORMER.	(min)	lon
				(M+H)*
	64		2.76	500
		Г Он		
	65 65	Bloom .	2.63	472
	66	, on	2.55	476
- Selektrik degeneraturan persenggan bersara an		S S OH	Enter the control of	room generalis suo
·	67		2.27	486
		, on		
	68	OH CH,	2.66	472

	69		2.58	458
, te a figur per anno a nomentamente e o e es	akkii art irkka rapitalise	H ₃ C N F OH		
	70	P OH	2.71	485.73
utta Jalan tait unnan milin appobaataan na a sa	71		2.22	472
		H ₃ C N		
	72	O CHA	2.22	472
	73		2.26	514
А. Беревичное принциполняющих ком ин.	474 monument		2.35	500/***
	75	OH OH	2.24	486

WO 2004/035556 PCT/EP2003/011423

Example 76

00R

5-Fluoro-1-methyl-3-[(4-{4-[3-(2-methylpiperidin-1-yl)nronoxylphenyl}niperazin-1-

Example 76

10

15

5-Fluoro-1-methyl-3-[(4-{4-[3-(2-methylpiperidin-1-yl)propoxy]phenyl}piperazin-1-yl)carbonyl]-1*H*-indole (E76)

5 E76a: 1,1-Dimethylethyl 4-(4-{[3-(2-methyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperazinecarboxylate

1,1-Dimethylethyl 4-{4-[(3-chloropropyl)oxy]phenyl}-1-piperazinecarboxylate (D9) (1.6g), was dissolved in 2-butanone (10ml). Potassium carbonate (1.38g) and a catalytic amount of potassium iodide were added, followed by 2-methylpiperidine (0.99g). The mixture was heated at reflux for 72 h under nitrogen. The reaction mixture was diluted with water and extracted with dichloromethane. The organic phases were separated using a hydrophobic frit, combined and evaporated *in vacuo*. The residue was purified on a 100g silica SPE bond elut cartridge, eluting with a gradient of 0% to 20% [0.880 ammonia-methanol (1:9)]-dichloromethane mixtures, to give the title compound (1.66g). LCMS RT= 2.48min.

E76b: 1-(4-{[3-(2-Methyl-1-piperidinyl)propyl]oxy}phenyl)piperazine

1,1-Dimethylethyl 4-(4-{[3-(2-methyl-1-piperidinyl) propyl]oxy}phenyl)-1piperazinecarboxylate (E76a) (1.66 g) was dissolved in dry dichloromethane (25 ml) and
stirred under nitrogen. 50% Trifluoroacetic acid in dichloromethane (5ml) was added,
and the mixture was stirred at room temperature for 4 h. Saturated sodium bicarbonate
solution was then added and the mixture was extracted with dichloromethane. The
organic phase was separated using a hydrophobic frit, and evaporated *in vacuo*,
however, most of the product was in the aqueous phase. The product was removed
from the aqueous phase using an OASIS cartridge, washing with water and eluting with
methanol, and further purified using an aminopropyl bond elut cartridge, eluting with
dichloromethane and then SCX cartridge, eluting with 50% [0.880 ammonia-methanol

WO 2004/035556 PCT/EP2003/011423

(1:9)]-dichloromethane to give the title compound (0.94 g). LCMS RT= 1.01min, ES+ve $m/z = 318 (M+H)^{+}$

E76c: 5-Fluoro-1-methyl-3-[(4-{4-[3-(2-methylpiperidin-1yl)propoxy]phenyl}piperazin-1-yl)carbonyl]-1H-indole

A solution of 5-fluoro-1-methyl-1H-indole-3-carboxylic acid (19.3 mg) and O-(1Hbenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) (56mg) in DMF (1 ml) and diisopropylethylamine (0.035 ml) was stirred for 10 min before 1-{4-[3-(2methylpiperidin-1-yl)propoxy]phenyl}piperazine (E76b) (21.3 mg) in DMF (0.5 ml) was added. The mixture was stirred for 18 h and then concentrated under reduced pressure. A A SACROPHIC LIGHT WORLD-SOVERED AND A NA The residue was purified by SPE ion exchange chromatography on an SCX-2 cartridge

(1g). The cartridge was washed with methanol (3 ml) and the product eluted with 2M ammonia in methanol (2.5 ml), to give the title compound (15 mg) LCMS RT = 2.42 min, ES+ve m/z 493 (M+H)*.

15 **Examples 77-224**

Examples 77 to 224 were prepared in an array format in vials using a solution of the appropriate carboxylic acid (0.1 mmol) in DMF (0.5 ml) and a solution of O-(1Hbenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) (0.15mmol) in DMF (0.5 ml) and diisopropylethylamine (0.2 mmol). Each vial was shaken manually and stood for 10 min, before a solution of the appropriate piperazine (selected from D18-D23 or D46 in the case of Example 99) (0.067 mmol) in DMF (0.5 ml) was added to each reaction mixture. The vials were left to stand overnight for approximately 18 h at room temperature. Each solution was then added to the top of a preconditioned SCX-2 SPE cartridge (1g). The cartridge was washed with methanol (3 ml) and the product eluted with 2M ammonia in methanol (2.5 ml), into pre-weighed vials. The solutions were evaporated to dryness on the genevac to provide the products (Examples 77-222). Examples 151, 154, 162-171 and 206-222 were further purified by mass directed autopreparative HPLC to provide the products as trifluoroacetate salts.

30

20

Example	Structure	RT (min	Mass ion (M+H) ⁺
77	H _o c.	2.36	438

A A RECORD HALL TO A SERVICE DESCRIPTION OF THE PROPERTY OF TH

AND THE STATE OF T

-	78		2.52	464
·	79	H,c CH,	2.55	466
. The first factor is the control of	80 Americanos		2.44	452
	81		2.74	484
	82		2.52	436
ullufulfelde de et al en et el petit e especiel sons en en en e	83		2.74	480
	84		2.58	476

		O F		
TO MERCING HER CHARLES TO SERVE AND A SERVER	92	and the second	2.23	456
		H _C -8		
	93	F 5 th	2.76	464
	33		2	
		S CH.		
			ĺ	
		R	204	404
	94		2.24	424
] 1	
		OH OH		
	05	8	2 16	468
ETAMORINELLINGOSTA MARABOLISTA KOLLIN	95	Contraction of the second seco	2.16	
		l o l s		
		ÇH,		
		<u> </u>		
	96		1.87	463
	•			
		H ₂ C		
	97		1.96	463
	1	J.,		
		"		
STATESTICAL STRUCTURE CONTROL STRUCTURE AND A		A L	4 0 7	407
	98		1.85	467
		р н,с- ^М -сн,		
,				
			 	461
	99		2.11	461
		l V		

					•
	100		2.37	484	
्राकृतिकृतिकार्यक्रम्यः । स्थानः । इत्यानिकारिकार्यक्रम्यः । स्थानः ।	and the second second second second	MATERIAL MATERIAL CONTROL CONT	the period to the	nes ot on exist teleplate describe	elektrik bir kanale kunna mang amun na kanale kan di bir ki ki ki ki ki di bir ki di bir di bir di bir di bir d Bir di bir d
	101		2.11	485	
	102	CH,	2.05	473 475	·
STANSONS AND SOMETHING SO	103		2.07	460 462	ender er den septimber som en semtel open til et som har for som kommen en sig en som kommen. De som kommen so
Angle Park Control of the Control of					
	104	Phic LH ₃	2.07	478	
	105		2.18	476 478	
The Residence of the State of t	106	CH, CH,	2.13	466	espera en procedentar por estado estado estado en 1870, por esta para liberar los comos del como del como los c
		CH, CH,			
	107	Сн,	2.05	440	

	108	CH ₆	2.20	450
				,
		H,C	me gan hall a profit to ma	
t ya dagan kata ta kata da kat Kata kata da k	109	i ch,	2.31	464
		CH,		
	110	CH ₃	2.31	464
		H ₃ C CH ₃		
	111	H,C CH,	2.29	464
CAPACIA DISCLUMENTA CONTRACTORISTA DE CAPACIA DE CAPACI	enga an ungarian antahungunan	Control of the Contro	es you to a sent to est	१ वर्षः २० १ १ १ १ १ वर्षः हेस्स
	112		2.22	462
	113		2.07	436
		H _s C CH _s		
કાં મુખ્યત્વે કહ્યું છે. જે	114	SH SH SHE SHE SHE SHE SHE SHE SHE SHE SH	2.07	436
	<u> </u>			

TO THE PROPERTY OF THE PROPERT

	115		2.12	476	
				478	
			1		
	116		2.13	448	•
STANDARD CONTRACT STANDARD CONTRACTOR AND A	ang transfer on the transfer of the second	AND THE PROPERTY OF THE PROPER	en o la santa e es	ess money a service sur-	properties the company of the compan
			1		
	117		2.26	480	
		H,C OH, CH,			
	118	OH, OH,	2.29	478	
		H ₃ C CH ₃			
		CH,			
	119	S ^N	2.15	485	response to the contract of th
erentaria de la como esta de la como de la c	a (na a Palitic) a como como la fina de transferio de Palitico (Palitico)	from the recipion of the section of	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
		\			
	120		2.52	472	
THE STANDARD SECURITION OF STANDARD SECURITION OF STANDARD SECURITIONS OF STANDARD SECURITIONS OF STANDARD SEC	s		10 . 10 . 10 2 15 15 15 15 15 15 15 15 15 15 15 15 15	22, 112011 222,173	properties of provincial actions are provincial and the last control of the contr

	121		2.52	452
		H,C CH,		
	122	, , , , , , , , , , , , , , , , , , ,	2.63	475
on progressive and order orderation and a reco	NOT FOR THE PROPERTY.		r kama nu mai lu	en une e secceso de
	:	NE CON		
	123	N.O.	2.53	464
		N ₁ O CON,		
	124	N _a c D	2.53	480
•		N ₂ C O		
tistiski festreliseksi oonel, asiat etä forekkissä keise esi.	125	Mark delignored Codes	2.60	464
		**		
	126	CH ₃	2.47	468
	120		2.41	400
		MgC - M. MgC - Mg -	i e komis i mis l	ng Marie grankiye b
TO A PROPERTY OF THE PROPERTY OF THE	the contract of the second second	the same of the sa		

	127	**	2.59	464
LT (A PALACIDER), COST E TELA COST PORTRADO ASPARAS.	er (201 eta 11 de desembro de primarence)	He I	Estrick, edition	ng sink to a baka tagu s
		CH,		
	128		2.61	537
	:			
	129	,	2.37	475
		3000		
		City Carl		
er begen daz errek izan da kanasan kon ar	130	High and the state of the state	2.58	534
		\		
		Q		
•		COL,		
	131	H.C.	2.66	518
				520
		N_cH,		
a proposition in the first of the second section of the second section in the second section is the second section of the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the second section in the second section is the second section in the section is the second section in the section is the second section in the section is the sec	ļ	Control of the second s	\$ 470 to 100 to 1	· · · · · · · · · · · · · · · · · · ·
	132	, , , , , , , , , , , , , , , , , , ,	2.54	494
·		N,C CN,		

,						
	133	\\(\sigma\).	2.76	504		
			1 '			
		- CH	<u> </u>			
	134	HC C	2.60	478		
THE SECTION AND CONTRACTORS SERVICES AND A THE	etija era i tradicija areketekom		. # 16-77 7-1 7-1 7-5	egg commer subjection.	оружен не в напрости в принский в оружений на принский принский принский принский принский принский принский п Принский принский пр	··· •
			1 '			
			'			
ļ	·	ا مر	1			
,) CH,	1			
		46				
!	135		2.60	517		
		and and				
		СМ,				
	136	EH,	2.65	588		
	130	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	2.00	1		ļ
TO RESIDENCE AND A VICE OF STANDARD SERVICE OF THE	and the second second	AND THE REPORT OF THE PROPERTY	is want to one	a the control of the properties.	by and the distribution of the control of the contr	. 6 - 6 - 7
CONTRACTOR AND	Philippin Carran access					
		CH,				
·		CH, HSC	1.00			
	137	JQ .	2.83	579		
		and the				
				<u> </u>		
	138	M.C.	2.60	476		
n en bleggen proposition de la proposition de la pr	a agreement in a december to be the	and the state of t	rail a samt hom	g - contracts - programs	a popular de descripción de para de restrict que a mais conservada, anticolorada con la colorada con conservad	" &"
		4		}		
		~ cn,				
		Ha			لـ ا	

THE PROPERTY OF THE PROPERTY O

<u>_</u>					
	139	moot.	2.63	536	
	140	Br. CH.,	2.69	542 544	
i di mining penggangan kanan kanan dan penggan dan dan dan dan dan dan dan dan dan d	, and the second second second	Name of the second seco	alie seria a er	, aga staning i dengaliy	province and approximation of the contract of
	141		2.62	528 530	
		H ₂ C CH ₃		, t	
4	142		2.68	589	
- Lo translation de la company de la comp	igang til som i til kinasina taganin k	H ₂ C	es, e genta te m		in province de contracte and contracted and a training of the contracted from the first of the contracted and the contracted an
	143	H ₀ C H ₀ C	2.61	521	
	144		2.58	478	
ः व त्याचा विश्वविद्यान् द्वाच्याः स्वत्यं व त्याचा स्वयं विश्वविद्याव्याच्या स्वयं न	i, ang pangangan pangangan pangan	CHA HO	Now a series to the	. ALL THOUSE CRIMENT	Bus kontroller statistick fra se mand directivativa vist, vali i fervis visti i milijest fervis vis

_				
	145		2.70	492
	146	H,C, C,	2.81	506
		cH _s		
i a dan kadan kada kada kada kada ka	gastalist and strainteenstanders	portion of the following control of the control of	, w ports to resi	, the transfer expensively. B
	147	CH ₆	2.77	522
		H ₂ C CH ₃		
	148	M ₂ C + A	2.77	506
	149	H ₀ O	2.59	464
्रतः । १९४५ व्यक्ति विद्यायाः १८४८ व्यक्ति । १९४८ व्यक्ति । १८४४ व्यक्ति ।	autorium makkumu puomin	H,C CH,	, w parts to ma	and the second s
	150	H, C	2.57	464
		H ₂ O CH ₃		

	151	\Diamond	2.27	486
,				
		MC F OH		
	152	W.°	2.60	478
The Petropic Lister State difference as a rece		Mo + Hook		
	153	Hack to the state of the state	2.63	494
	154	CH, & CH,	2.36	466
চাৰে প্ৰচাৰ চাৰে নামৰ বা মাজে প্ৰচাৰকাৰ্যন্ত কৰাৰ কৰে।		Magnagement and charge control for the control of t		
	155	щс-о-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-	2.36	466
	156	CH,	2.65	478
natur batean ett inne natur de senere se en	Palai san in bibbosho nga rismb	н,с		

	157	H _s c \	2.54	464
		H,C L		
	158	H ₂ C CH ₃	2.40	450
STEELER STEELE	aggrand in the property and the second	MENGENE SOUTHER STEELE ESTELLE L'ESTELLE L'ESTELLE L'ESTELLE L'ESTELLE PRÉSE DE STETTE L'ESTELLE PRÈSE SE L'ES	e extra none	nga (thomas ag debah kasi) þess
		HC N		
	159		2.42	493
	160	H ₄ C CH ₃ O CH ₃	2.42	561
के राज्याच्या विक्राणिक विकास विकास है। यह स्वता विकास स्वता विकास विकास स्वता विकास स्वता विकास स्वता विकास स	161	он, о ^о сон,	2.51	500 502
		4,0		

	162	🖒	2.66	492	
on near the properties of the control of the contro	, and the state of	CHAIR CONTRACTOR OF THE CONTRA	- N., W. B. (PS) N. (PS)	. The transmisteriores	and the contraction of the second section sectio
	,	,		1	
		1			
	163	, un	2.60	528	
		10		530	
			'		
	ļ		ļ'		
	164		2.54	522	
			<u> </u>	d	a proportion de companya companya proportione de la marca de la companya del companya de la companya del companya de la companya del la companya de la companya del la companya de la comp
STORESTATEMENT HAR STEPHEN WERE 404 4	and the or the second order	gent regression and water transaction and size or a supermention of our and on an or and or an or and or an	No. w sector to the		Report of the National Assessment of the second of the sec
	165		2.51	462	
		0-1-0-0-6			
	1				
		+4.			
	166		2.76	565	·
l	1	0			
			The same to ma	en erente a transper	Beginner in the constitute of the second
Control to the complete that the control to the con	167	and the state of t	2.55	504	
		10-2-0-4,	2.00		·
1	1				
1		r- 			
,		j 54	1	<u> </u>	١.

١	400	на—Сн,	2.51	464	
	168	~ ~~~	2.01	40-1	
o en transista de la companya de la	and the second second	and had helden de see the partition of the partition of the comment of the partition of the	., w pomis ne mas	, the transported and the second	menteriore provincia estados conflicidades (1931-1930), alto finales, e toris en estados (1930-1930), al
	1	+%			
	169	Ones	2.67	490	
		۰			
}	170	1 - }€.	2.45	480	
ł	170	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	2.40		ı
		.1.0			
ł	171		2.57	504	
o control de descripción de la contrata del contrata del contrata de la contrata del contrata de la contrata del contrata de la contrata del contrata del la contrata de			, e sient ni ne	1 1	menter en en comune en mas pombre mente mente de comitación de la comitación de la comitación de la comitación
		1		{	
	172	\rightarrow \right	2.63	478	
	''-				
J					
		Pr.			
	}	H ₄ C CH ₄			
	173	\bigcirc	2.65	494	
		€ CON			
. 5 (* 1927) P. Politik (1923), 1943 (1924) P. Politik (1924) P. P	de la filipio de la compania del compania de la compania del compania de la compania del la compania de la compania del la compania de la com	The first of the f	1 . # 3 e*N3 %, #S	a . The standard feel har east	Beginner of the community of the communi
		Me ()	}		
	L	т, с _т	1		J

WO 2004/035556 PCT/EP2003/011423

	174	CH ₂	2.69	478
		H ₂ C		
allen programment og skipen for skipen er er er	Alle ter in property posterior	and the second s	e press of the c	real transfer of programs of pr
	175	CH,	2.56	482
	176		2.49	500 502
egitak biga kipaturan kepitan di Samatikan kipat ang	tiger om en til det en	СН		
	177	M ₂ C C C C C C C C C C C C C C C C C C C	2.66	478

ſ		H _s c. ∕ ≥er		 	1
	178		2.55	514 516	
				310	
			, ,		
		\ \int \^\ \ \ \	,		
er en en flegge fan de skriver en fan de skriver f	State in Section (Section 1997)	CH2	service to miss .	the streets of traditions. B	gawan wangan kangan kangan pangan mangan mangan bangan Tangan, Angan, Angan, Angan, Angan, Angan, Angan, Angan
}	179	P**	2.47	448	
	170		۲. ٦ ،	440	
			i	!	
			ļ	.!	
		\ \ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\		1	
		کم			
		O day			
	180	\triangleright	2.72	551	
		— — N _{cH}		1	
		\$ C C C C C C C C C C C C C C C C C C C		!	·
o en en la proposició de la companya de la company La companya de la co	New root is a sound an observation of		v samta na msa la	ang ar and a sign high digital B	рынга ен менамирин корын америкалык тарын үйрүүнү байын байын байын байын байын алым байын айын айын айын айы
	181	o-0	2.52	560	
·			1	!	
			<u> </u>		
		~° ^c			
)			
}	182		2.47	489	
	102		۷.۳۰	409	
on a substantial de la constantia de la co	All of the second second	CHI	e karas iku mer	recovering temperature	a quanti en persona a esta a esta de e
-					,

_			T	100	
	183	F	2.54	490	
			l		
		CH₃			Basiner en de rettassan en sa sante tana esta se su statuer. Per esta su
es contrat personalistica de la contrata de la cont	184	H _I C CH,	2.47	450	
		~~Nor.			·
	185	CH ₃	2.60	476	
	100				
					-
	186	A COL	2.39	466	
uguntes tigang ang ang ang ang ang ang ang ang ang	and the second of the second o	AND AND THE STORY AND	in, was great to make	with an amen's of dista print a star	e desemble de contrata de estado estado de entre entre entre de estado de la Pelentido dos entre entre entre e La composição de la Pelentida de estado de entre e
		H ₁ C-0			
·	187	CI.	2.53	491	_
		, N			
				l.	
				ļ	
		No.			
SOFT TO BE PROTECTED AND REPORT OF THE PROTECTION OF THE PROTECTIO	ka est ett i tradiciolei teiteste	CH	m	is a specificación despesario	on Bellevier er den sæmlike en til på grætt til tær ett gift vænt fillet i Felikon, ett fil en stellt fill vil

	188	CH,	2.63	478
		H,C CH,		
	189		2.64	494
ele el marine, menerolare de la companya de la comp	ang ang talah ang mangkang kanang	NG CH ₃	, , , , , , , , , , , , , , , , , , ,	
	190		2.68	478
•				
		MC COL		
	191	o CH,	2.58	482
च्छे प्रस्तात विक्रे के हिन्दु के हिन्दु के स्त्रीत के स्त्रीत के स्त्रीत के स्त्रीत के स्त्रीत के स्त्रीत के स्त्रीत के स्त्रीत के	tigadali est. Italia esta tigat	magniga nag nagagi (mag) magagi nagagi nagagi nagan naga naga na nagan nagan na nagan na nagan na nagan na naga	and the second second	es i es como proper
		н,с		
·	192	\$\frac{1}{2}\$	2.55	464
		mc d		
	L	CH,	<u> </u>	

	193	H, C	2.44	450
	194	H _C C N	2.47	500
	10-4		2.71	502
i i en familia de la compositiva de la		H,C	went none o	egg transcent personage. 2
all appropriate the second of principles and second appropriate the second	195	H _C CH ₁	2.66	478
	196	N.C. C.	2.44	508
	197	H _C CH,	2.44	448

TO STATE OF THE PARTY OF THE PA	198	and response on man enterior continues land of comments only or other son	.2.71	.551	giant nei den nettetta kattalah petit hil detak intervisional sebesah kan pendangan basa pendangan basa bija m
			<u> </u>		
	400	\$14,	2.52	560	
	199)	2.52	300	
		√ e			
		→			
	ļ	Y			
	200	сн <u>.</u>	2.46	489	
	200		2.40	405	
- SO CONTRACTOR CONTRACTOR STATEMENT AND A FACE	Company of the second construction of the second	and the state of any and the Towns are now a special and a series of the second second second second second second	A CONT. NO. OR .	AND STORYS OF CONTRACTOR OF	apper komunika semengan kanasah mengerakan mengerakan seminakan sebesah kentan berangan sebagai berasah di Seb Berangan seminakan s
		CH,	ŀ		
		₩			·
	201	F—F	2.50	490	· .
				1	· .
•					
		\	i		
		<u></u>			
		N.C.			
	202	H ₃ C	2.46	450	1
	202	·		.55	
		N. Ors			
TO SAN PLANSANCE CARPORATE CONTRACTOR SERVING NO SERVIN	Tarian resourcessioner	ta nagrasagana, englasia tegesari, salen eta, binen i salenente akente konan en an ekiloni ben hin	.	, legg the serve of grant and hearth and	and the second section of the second section of the second
		N N	1		
			1		·
	·	°			
)	_h_			
	L	H ₃ C		J	.]

	203	н,с О	2.62	476	
The state of the s	the second second	PER CORP MAN TO LANGE ESSENANT CONTRACTOR SERVING CONTRACTOR CONTR	e service of the con-	and account of the second section of	namen en managan kalabah salabah salab
al and the first than the first than the second of the	204	CH,	2.39	466	
		н,с О СН,			
	205	C C	2.52	490 492	
i Description de la constitución d	an (The State of the Displace of the Confidence	San de la companya del companya de la companya del companya de la companya del la companya de la	a service, mix	, chay or notes a grandfalleri B	в ражения матрамента на применент при
		H _C			
	206	CH,	2.40	508	
	:				
	007	CH ₀ CCH ₃	2.37	496	
	207		2.57	430	
			:	į	
STORESTANDARD STELLARS, STORE STORESTANDER AND A	gan 22 anii 20 biray da an		santa sa mpi	, to many processor	parameter provinces and a secure and a security of the last of the second of the second of the second of the second
		CH ₉		<u> </u>	_

	208	2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2	2.35	478	
		H,C CH			
TO THE PROPERTY OF THE PROPERTY OF THE	est en transmission	en nagrina pour la verbytan estrument une restricte en la concernation en est et en est et en en en en en en e	e samo na espa	may therefore determine dates to	tal port tide into 1919 societates. I talifato, del representate del propieta de propieta de la propieta de propieta
	209	H.C	2.27	464	·
	040	CH, CH,	2.37	504	
Find no no new York (finding the St. Line of Contains (finding (finding finding finding finding finding finding	210			506	gaverner den nærgalvændstagen præster ækku. Myst vikk vikk læt i den krive kilon kilon og elle line vikk læt
	211		2.26	514 516	
	212	Br Cole	2.34	528 530	
is constructive and constructive and services and services and services and services and services and services	A CONTRACTOR OF THE CONTRACTOR	and the state of t	1	, and an entry of the hoteless. I	aguerro e em canada e estado a transferir en 173 de 1840, em combio do los colos de 1860 de 1860 de 1860 de 18

	213	He-for the second secon	2.00	514
		NC COL		
STREET, THE PROPERTY OF THE PROPERTY AND A	214	l to	2.28	522
		H,C CH,		
	215	Hon Hon	2.26	462
o no establishe beste do establishe establishe establishe establishe establishe establishe establishe establish	216	CM,	2.57	574
·		No. Co.		
	217	P OH CH,	2.30	503
Li chin shiki deput iseku ka njeka nekidikomeksi se nek	218		2.30	504
		ne-		

proportion and registration to the engineering of the color of the engineering of the engineering

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:				
☐ BLACK BORDERS				
\square IMAGE CUT OFF AT TOP, BOTTOM OR SIDES				
☐ FADED TEXT OR DRAWING				
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING				
☐ SKEWED/SLANTED IMAGES				
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS				
☐ GRAY SCALE DOCUMENTS				
LINES OR MARKS ON ORIGINAL DOCUMENT				
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY				

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.